CYNATA THERAPEUTICS LIMITED (ASX:CYP) - CYP Trading - post Fuji validation, page-218 - HotCopper | ASX Share Prices, Stock Market & Share Trading Forum

Originally posted by Sector ↑

https://www.nabtrade.com.au/investor/insights/latest-news/news/2019/09/four_biotech_stocks

4. Cynata Therapeutics (CYP:ASX)

Market capitalisation: $163 million
One-year total return: 31.8%
Analysts’ consensus price target: $2.50
Cynata Therapeutics was also one of our promising stem-cell stocks in October 2016, when it was trading at 71 cents: CYN has also hit the headlines this month, announcing a deal with Japanese company Fujifilm by which the latter will exercise its option to license one of Cynata’s stem cell-based treatments coming out of its Cymerus mesenchymal stem-cell technology platform.
Mesenchymal stem cells, or MSCs, are found in the body’s bone marrow and connective tissue. They have immune-suppressive and immune-regulatory activity, and migrate to sites of affected tissue to control local inflammation. In 2015, Cynata achieved a world-first breakthrough of manufacturing MSCs to therapeutic standards using induced pluripotent stem cells: prior to this breakthrough, manufacturing MSCs required a continuous supply of new tissue donations, but CYP’s technology using induced pluripotent stem cells gives it an effectively limitless starting material.
The Fujifilm deal was ready for the green light earlier this year, but in March, the two parties announced a six-month delay: that caused a 40% slump in CYP’s share price, but all is forgiven now on the part of skittish investors.
Fujifilm will license CYP-001, Cynata’s treatment for graft-versus-host disease (GvHD), a rare but potentially lethal complication from bone-marrow transplants, including for leukaemia. GvHD happens when immune cells from a transplant (the graft) see the recipient’s cells (the host) as foreign, and attack them, causing inflammation throughout the body. Usually, severe cases of GvHD are treated with high-dose steroids and immune-suppressants, but in about half of cases the patient fails to respond to treatment – and the consequences are usually fatal.
However, CYP-001 treatment, involving an infusion of millions of stem cells, appears to work to control and mediate the immune response. A Phase I clinical trial in 2018 showed that 14 out of 15 GvHD patients treated with CYP-001 showed improvement, with 8 of 15 having their GvHD signs and symptoms “completely resolved.”
Cynata will receive $US3 million from Fujifilm as an up-front fee, and stands to get up to $US43 million more in future milestone payments, as well as 10% royalties if the drug is successfully commercialised.
Cynata is also working to develop stem treatments for osteoarthritis and critical limb ischemia, a reduction of blood flow to the extremities that can lead to amputation and death. The company is preparing Phase II trials for its stem cells in relation to both conditions.
In July, Cynata received a $200 million takeover proposal by Japan’s Sumitomo Dainippon Pharma, at $2 a share. The company says it will update the market about the approach shortly: obviously, its response will have a significant impact on whether CYP will stay independent long enough to attain where analysts see its price as potentially heading.

There goes that $2.50 again!

Expand

Haven't this been rounded up to $3
SP starting with a $3 looks much betterer!

No.	Vol.	Price($)
1	20209	25.0¢

No.

Vol.

Price($)

20209

25.0¢

Price($)	Vol.	No.
26.0¢	36715	1

Price($)

Vol.

No.

26.0¢

36715

No.	Vol.	Price($)
1	20209	0.250
2	49573	0.245
2	102000	0.240
1	100000	0.235
2	15173	0.230

No.

Vol.

Price($)

20209

0.250

49573

0.245

102000

0.240

100000

0.235

15173

0.230

Price($)	Vol.	No.
0.260	36715	1
0.265	8119	2
0.270	30000	1
0.290	1900	1
0.295	183892	1

Price($)

Vol.

No.

0.260

36715

0.265

8119

0.270

30000

0.290

1900

0.295

183892

(20min delay)
Last 25.5¢		Change 0.000(0.00%)		Mkt cap ! $45.80M

Open	High	Low	Value	Volume
25.5¢	25.5¢	25.5¢	$3.545K	13.9K

CYP Trading - post Fuji validation, page-218

PAM secures high-grade Chilean copper play in strong territory

Brine and shine: Arizona Lithium wins early stage eco approval to commence wellpad #2 at Prairie

Biome unveils three year revenue target up to $85M – but are 3Y targets enough to excite?

$550 million Jabiluka uranium offer comes unstuck as Government rules lease won't be renewed

KGL hits copper-silver-gold-zinc-lead massive sulphide intersection in NT

Featured News

Buyers (Bids)

Sellers (Offers)

Featured News

CYP Trading - post Fuji validation, page-218

Top Stories

PAM secures high-grade Chilean copper play in strong territory

Brine and shine: Arizona Lithium wins early stage eco approval to commence wellpad #2 at Prairie

Biome unveils three year revenue target up to $85M – but are 3Y targets enough to excite?

$550 million Jabiluka uranium offer comes unstuck as Government rules lease won't be renewed

KGL hits copper-silver-gold-zinc-lead massive sulphide intersection in NT

Featured News

Buyers (Bids)

Sellers (Offers)

Featured News